PML-RARA Translocation, t(15;17) by RT-PCR, Quantitative
2002871
 
Time SensitiveTime Sensitive
Additional Technical InformationAdditional Technical Information
Ordering Recommendation
Provides genetic confirmation of APL. Predict relapse risk and monitor for minimal residual disease post-consolidation therapy.
Mnemonic
PML QNT
Methodology
Reverse Transcription Polymerase Chain Reaction
Performed
RNA isolation: Sun-Sat
Assay: Sun, Tue, Thu
Reported
2-7 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA) or bone marrow (EDTA).  
Specimen Preparation
Transport 5 mL whole blood (Min: 1 mL). OR 3 mL bone marrow (Min: 1 mL). Specimens must be received within 48 hours of collection due to lability of RNA.  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Serum or plasma. Frozen or clotted specimens. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed specimens.  
Remarks
 
Stability
Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable  
Reference Interval
By report
Interpretive Data
Refer to report.

See Compliance Statement D: www.aruplab.com/CS
Note
This assay qualifies as COG approved for the AAML0631 study.
CPT Code(s)
81315
Components
Component Test Code*Component Chart Name
2002872PML-RARA Translocation, t(15;17)
2002874PML-RARA Translocation, t(15;17) Quant
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, contact interface support at interface.support@aruplab.com.
Cross References
  • AMPL' APL
  • APL MRD
  • APL Post-consolidation therapy testing
  • PML-RARA fusion types, A, B, B variant
  • PML-RARA long, short, variable types
  • PML-RARA S, L, V forms
  • PML_RARA fusion types
  • Quantitative PML
  • t(15;17)